01 / Vendor Profile
MAPP BIOPHARMACEUTICAL, INC. Federal Contracts and Awards
UEI M9V9QTHR1H28 · CAGE 417U0
Federal contract activity attributed to this vendor identity across FY 2020–FY 2026. Obligations are FPDS accounting transactions, not company revenue.
02 / Federal Business Size
Federal contract market at a glance
Measured consistently across FY 2020–FY 2026.
Across FY 2020–FY 2026, FPDS records attribute $394.00M in net contract obligations to MAPP BIOPHARMACEUTICAL, INC. across 164 contract actions. Net obligations include positive obligations and later deobligations recorded during the same period.
03 / Spending Trend
MAPP BIOPHARMACEUTICAL, INC. contract spending by year
Annual net obligations show whether recorded federal business expanded or contracted, while actions and customer counts show the breadth of that activity.
Total obligations$83.12M
FY 2026ObligationsHistorical spending range
| Fiscal year | Obligations | Actions | Federal customers | Change |
|---|---|---|---|---|
| FY 2020 | $24.69M | 7 | 2 | — |
| FY 2021 | -$42.74M | 15 | 3 | −273.1% |
| FY 2022 | $217.01M | 33 | 3 | +607.7% |
| FY 2023 | $60.85M | 19 | 2 | −72.0% |
| FY 2024 | $2.97M | 26 | 2 | −95.1% |
| FY 2025 | $48.11M | 38 | 2 | +1,519.1% |
| FY 2026 | $83.12M | 26 | 2 | +72.8% |
04 / Federal Customers
Which federal agencies buy from MAPP BIOPHARMACEUTICAL, INC.?
Ranked by net obligations during FY 2020–FY 2026.
| Agency | Code | Obligations | Actions | Vendor share |
|---|---|---|---|---|
| 7505 | $391.69M | 141 | 99.4% | |
| 2100 | $2.20M | 10 | 0.6% | |
| 97DH | $102.5K | 9 | 0.0% | |
| 9761 | $12.6K | 1 | 0.0% | |
| 9763 | $0 | 3 | 0.0% |
05 / Contracting Offices
Which contracting offices buy from MAPP BIOPHARMACEUTICAL, INC.?
Ranked by net obligations during FY 2020–FY 2026.
| Office | Code | Agency | Obligations | Actions | Vendor share |
|---|---|---|---|---|---|
| 75A501 | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE | $391.69M | 141 | 99.4% | |
| W911QY | DEPT OF THE ARMY | $999.0K | 3 | 0.3% | |
| W81XWH | DEPT OF THE ARMY | $700.4K | 5 | 0.2% | |
| W911SR | DEPT OF THE ARMY | $500.0K | 2 | 0.1% | |
| HT9425 | DEFENSE HEALTH AGENCY (DHA) | $71.7K | 6 | 0.0% | |
| HT9426 | DEFENSE HEALTH AGENCY (DHA) | $30.8K | 3 | 0.0% | |
| HDTRA1 | DEFENSE THREAT REDUCTION AGENCY (DTRA) | $12.6K | 1 | 0.0% | |
| S0514A | DEFENSE CONTRACT MANAGEMENT AGENCY (DCMA) | $0 | 3 | 0.0% |
06 / Top NAICS Industries
Which industries define this vendor’s federal work?
| NAICS | Description | Obligations | Actions | Customers | Share |
|---|---|---|---|---|---|
| 541714 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) | $399.67M | 77 | 3 | 101.4% |
| 541715 | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) | $41.86M | 26 | 1 | 10.6% |
| 541720 | RESEARCH AND DEVELOPMENT IN THE SOCIAL SCIENCES AND HUMANITIES | $1.23M | 31 | 1 | 0.3% |
| 541380 | TESTING LABORATORIES | $601.1K | 7 | 2 | 0.2% |
| 325413 | IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING | $201.8K | 7 | 1 | 0.1% |
| 541711 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY | -$49.56M | 16 | 3 | -12.6% |
07 / Top Product and Service Codes
What products and services does the government buy from this vendor?
| PSC | Description | Obligations | Actions | Customers | Share |
|---|---|---|---|---|---|
| 6505 | DRUGS AND BIOLOGICALS | $237.33M | 38 | 1 | 60.2% |
| AN13 | HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT | $198.31M | 61 | 3 | 50.3% |
| AJ11 | GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH | $5.63M | 14 | 1 | 1.4% |
| AD25 | R&D- DEFENSE OTHER: SERVICES (OPERATIONAL SYSTEMS DEVELOPMENT) | $1.50M | 6 | 2 | 0.4% |
| AN12 | HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $1.24M | 35 | 3 | 0.3% |
| 6550 | IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $201.8K | 7 | 1 | 0.1% |
| AN11 | HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH | -$50.21M | 3 | 1 | -12.7% |
08 / Competition Pattern
How was MAPP BIOPHARMACEUTICAL, INC.’s federal work competed?
Competition categories describe the procurement path recorded on the underlying contract actions.
09 / Recent Contract Awards
What contract actions were recorded most recently for MAPP BIOPHARMACEUTICAL, INC.?
The latest recorded PIIDs connect this profile to the underlying federal award search.
| Award / PIID | Signed | Obligation | Agency / office | NAICS | PSC |
|---|---|---|---|---|---|
| HHSO100201600021C | Sep 30, 2026 | $0 | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE BARDA - ASPR / DAAPPO / BARDA DCMA | 541720 | AN12 |
10 / Interpreting the Profile
How should you evaluate MAPP BIOPHARMACEUTICAL, INC. as a federal contractor?
Read obligations, customers, markets, competition, and individual awards together. A large historical total indicates federal scale, but it does not by itself describe current backlog, commercial revenue, profitability, or future opportunity.
Separate obligations from revenue
FPDS obligations are government accounting actions and may include later deobligations.
Follow customer concentration
Agency and office concentration reveals where the vendor’s federal relationships are strongest.
Test market overlap
NAICS and PSC shares show whether the vendor competes in the same markets as your company.
Inspect the awards
Open the PIIDs to verify dates, offices, classifications, and transaction history.